anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tuberculosis (TB) and sarcoidosis are both granulomatous diseases. Here, we compared the immunological microenvironments of granulomas from TB and sarcoidosis patients using in situ sequencing (ISS) transcriptomic analysis and multiplexed immunolabeling of tissue sections. TB lesions consisted of large necrotic and cellular granulomas, whereas "multifocal" granulomas with macrophages or epitheloid cell core and a T-cell rim were observed in sarcoidosis samples. The necrotic core in TB lesions was surrounded by macrophages and encircled by a dense T-cell layer. Within the T-cell layer, compact B-cell aggregates were observed in most TB samples. These B-cell clusters were vascularized and could contain defined B-/T-cell and macrophage-rich areas. The ISS of 40-60 immune transcripts revealed the enriched expression of transcripts involved in homing or migration to lymph nodes, which formed networks at single-cell distances in lymphoid areas of the TB lesions. Instead, myeloid-annotated regions were enriched in CD68, CD14, ITGAM, ITGAX, and CD4 mRNA. CXCL8 and IL1B mRNA were observed in granulocytic areas in which M. tuberculosis was also detected. In line with ISS data indicating tertiary lymphoid structures, immune labeling of TB sections expressed markers of high endothelial venules, follicular dendritic cells, follicular helper T cells, and lymph-node homing receptors on T cells. Neither ISS nor immunolabeling showed evidence of tertiary lymphoid aggregates in sarcoidosis samples. Together, our finding suggests that despite their heterogeneity, the formation of tertiary immune structures is a common feature in granulomas from TB patients.
The invention relates to a cosmetic preparation, for the generation of a cosmetic coating with a metallic and multi-coloured shimmering appearance, comprising a liquid phase and PVD aluminium pigment. The PVD aluminium pigment has refractive structures with ca. 5,000 to ca. 20,000 structure elements per cm, a metallic aluminium component of 90 to 100 wt. %, based on the weight of the aluminium pigment and the pigment is contained in the cosmetic composition at 1.0 to 8.0 wt. %, based on the total weight of the cosmetic composition. The invention further relates to an artificial fingernail.
The minimalist footwear represents an alternative style of footwear wearing, which could allow the foot to move more naturally compared to the footwear wearing in conventional footwear. That footwear is characterized by no cushioning, wide toe box, zero foot drop, thin sole (1,5 - 8 mm), low weight, and high flexibility of footwear. This study aims to determine the effect of 6months of wearing minimalist footwear on the foot and lower limb's anthropometric and biomechanical parameters.

The study is designed as a parallel interventional study. The sample size consists of 50 healthy individuals divided into experimental and control groups by randomization. All participants undergo the initial examination and baseline and final measurement focused on the foot anthropometry and kinetics and kinematics of the foot and lower limb during walking. Besides, the experimental group undergoes a 6months intervention of wearing minimalist footwear, during which the participants will record their movement behavior by electronic diary.
KORSUVA (difelikefalin) is a kappa opioid receptor agonist. Difelikefalin is a synthetic peptide with a single stereoisomer and is present as an acetate salt. Difelikefalin acetate is a white to off-white powder with a molecular formula of C 36H 53N 7O 6•xAcOH (1.0≤ x ≤2.0) and a molecular weight of 679.4 g/mol (mono-isotopic; free base). It is soluble in water. The chemical name of difelikefalin acetate is 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid, acetate salt. 

The chemical structure is:

KORSUVA (difelikefalin) injection is supplied in a single-dose vial containing 65 mcg/1.3 mL (50 mcg/mL) of difelikefalin as a sterile, preservative-free, clear and colorless solution for intravenous injection.

KORSUVA is formulated as an isotonic 40 mM acetate buffer solution with an osmolality of 250 to 350 mOsm and a pH of 4.5.

Each milliliter of KORSUVA injection contains 50 mcg of difelikefalin (equivalent to an average of 58.3 mcg of difelikefalin acetate), 1.3 mg of acetic acid, 2.5 mg of sodium acetate trihydrate, 7.2 mg of sodium chloride (to adjust tonicity), and water for injection.
The treatment regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 30 mg, once per three weeks, 4 cycles in total), PD-1 inhibitor (Sintilimab, via intravenous infusion, once per three weeks, 4 cycles in total)), pemetrexed chemotherapy (via intravenous infusion, once per three weeks, 4 cycles in total) and radiotherapy. Whole brain LDRT will be administered at 3 cohorts with increasing dose fractions: 4 Gy/2f of 2 fraction (administered a daily dose of 2 Gy for two days) in group 1; 4 Gy/2f of 4 fractions (administered a daily dose of 2 Gy for two days, once per three weeks, 2 cycles in total) in group 2; 4 Gy/2f of 8 fractions (administered a daily dose of 2 Gy for two days, once per three weeks, 4 cycles in total) in group 3.
Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
This evaluation tests the effect of the MPC School Edition, the version of the MPC 5th Edition designed for implementation in school. This edition includes 9.5 hours of content implemented in 14 40-minute modules. Schools assigned to the MPC condition received MPC in a targeted class.
Despite decades of research into patient falls, falls and the injuries incurred continue to be a serious threat to patient safety. Fall rates continue to be unacceptably high. The purpose of this project is to increase the safety of a hospital room for patient mobility, using innovative simulation strategies and patient-centric design.

An innovative simulation environment will be built to enable rapid assessment of room layout and fixture positioning and patient stability. The results from multiple simulations will be used to fabricate a prototype room layout that will be tested by patients with Parkinson disease and reviewed and updated with input from other relevant stakeholders. A final room prototype will be built and tested. Results will be translated and shared with all stakeholders and disseminated for implementation.
<P>PROBLEM TO BE SOLVED: To provide a long lasting natriuretic peptide having a half life more excellent than the native form of ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide) and the modified forms of the ANP and BNP sequences disclosed in the related art.  <P>SOLUTION: The invention relates to long lasting natriuretic peptide (NP) derivatives. The NP derivative includes an NP peptide and a reactive entity coupled to the NP peptide. The reactive entity can covalently bond to a functional group on a blood component. In particular, the invention relates to NP derivatives having an extended in vivo half life, and a method for treating cardiovascular diseases and disorders such as acute decompensated congestive heart failure (CHF) and chronic CHF. Accordingly, there is newly provided the NP derivative having an extended in vivo half life when compared with one of native ANP or native BNP.  <P>COPYRIGHT: (C)2010,JPO&INPIT
OBJECTIVE: This study aims to investigate the effect of physical activity, body mass index (BMI), and levels of prostaglandins (PGF2α) urine on the occurrence of dysmenorrhea in adolescents.
METHODS: A total of 128 female students included in the study. The study was conducted from January to March 2023 using a cross-sectional design. This study utilized the Menstrual Symptom Questionnaire (MSQ) and gynecological examination with ultrasonography. The urinary prostaglandin (PGF2α) was measured using the enzyme linked immuno sorbent assay (ELISA). Data were analyzed using the chi-square test and logistic regression test.
RESULTS: The age range of the participants included in the study was 14-17, with a mean age of 15.85 ± 0.65. There was an correlation between physical activity, BMI, and urinary prostaglandin (PGF2α) levels with the incidence of dysmenorrhea in adolescents (p < 0.001). In multivariate analysis, it revealed that underweight, and had a high urinary prostaglandin significant correlated to primary dysmenorrhea with odds ratio 4.78 (95% confidence interval [CI] 1.98-11.54) and 4.88 (95% CI 1.98-12.08), respectively. High physical activity and overweight was not associated with incidence of dysmenorrhea in adolescents.
CONCLUSION: This study provides valuable insights into the correlation between physical activity, BMI, and levels of prostaglandins (PGF2α) in urine. A high level of urinary prostaglandin was found to be the most influential factor in the incidence of primary dysmenorrhea in adolescents. By addressing factors associated with dysmenorrhea in adolescents, healthcare professionals can potentially enhance well-being by reducing menstrual pain and encouraging a healthy lifestyle to prevent dysmenorrhea.
IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
It is well known that youth involved in the juvenile justice system have multiple problems, including an earlier onset of alcohol and drug use and higher rates of alcohol and drug use than their peers in the general population. Several recent innovative treatment approaches have been developed to address substance use and the multiple problems that these at-risk youth experience. What is less well documented, however, are innovative approaches to treat youth who are first time alcohol or drug offenders and who may just be beginning to experience problems due to their substance use. The investigators propose a 4.5 year study to adapt and test an efficacious group intervention among teens who have committed a first time alcohol or other drug misdemeanor offense. These teens have been referred by the juvenile Probation Department to a Teen Court program because they have not been found to need more serious intervention such as treatment or detention. The objectives of the proposed research are to: Aim 1. Design a developmentally sensitive intervention curriculum in which the investigators (a) utilize our previous work and components from relevant existing approaches targeting at-risk adolescents, (b) establish participant acceptance, and (c) establish feasibility of intervention delivery with the participants, providers and the proposed setting; Aim 2. Implement a pilot test of the revised intervention with an adolescent population of first time offenders in which the investigators (a) demonstrate our ability to retain sufficient numbers of this population; (b) ensure intervention fidelity throughout the course of the study and (c) evaluate participant satisfaction, group engagement, and group climate; Aim 3. Examine the impact of the intervention on cognitive and behavioral outcomes to determine (a) whether clinically significant changes in expectancies, perceived prevalence of peer use, self-change efforts, alcohol consumption, marijuana and other drug use, and related consequences occur; (b) if reductions occur, estimate the likely effect sizes, and (c) explore the mechanism of change for decreases in substance use and consequences through mediation analyses. Our study seeks to narrow the gap between research and practice and builds upon recommendations by NIDA's Blue Ribbon Task Force by conducting research in a nonacademic setting with a population at high risk for alcohol and drug abuse. This study will extend selective intervention research for at-risk youth, as it will be one of the first to examine the impact of a theoretically based selective intervention for first time juvenile Alcohol or Other Drug (AOD) offenders.
Based on previous literature and preliminary test results, the initial dose of pre-injection remifentanil is set at 1ug / kg. The dose of remifentanil is based on the patient's degree of myoclonus. If there is no myoclonus (negative response), the dose of remifentanil is reduced for the next patient until the patient develops myoclonus. If there is myoclonus (positive response), the dose of remifentanil will be increased in the next patient until the patient is free of myoclonus.
• Group A receive caudal block placing the patient into the left lateral decubitus position. Povidone iodine was used to sterilize the skin. The sacral hiatus was found by palpating the sacral cornu and a 22-G needle was placed through it. After passing through the sacrococcygeal membrane by using the loss of resistance method, the caudal epidural space was entered. Negative aspiration was used to make sure there was no blood or cerebrospinal fluid present and 0.25% bupivacaine was administered at a dose of 0.2 ml/kg. Once the procedure was completed, the patient was placed into the supine Position.

Group B US guided Dorsal penil block. General anesthesia induction was followed by skin sterilization using 70% alcohol in 2% chlorhexidine. The 5-10 MHz linear probe was placed at the penis root, making it possible to observe the corpus cavernosum, corpus spongiosum, dorsal artery and vein, and the deep penile fascia (Buck's fascia) on the transverse plane with gentle penile traction. The in-plane technique was then used to insert a 50-mm block needle toward the dorsal penile section from the lateral part of the penis root. The needle was then advanced from the hyperechoic superficial penis fascia (Dartos fascia) and the superficial sheath was passed. After advancing the needle into Buck's fascia, the needle was placed lateral to the dorsal artery, at a position between Buck's fascia and tunica albuginea. Negative aspiration was performed. US was then used to observe the distribution of the anesthetic while half of the total 0.25% bupivacaine dose (0.2 mL/kg) was administered (Fig. 1). Afterward, the same procedure was also performed on the other side of the penis.
The invention discloses a preparation method of a traditional Chinese medicine wine capable of moisturizing the skin and tonifying the liver. The traditional Chinese medicine wine is prepared from 250g of longan pulp, 120g of wolfberry fruit, 30g of angelica, 30g of chrysanthemum flower and 3500ml of white wine. The preparation method comprises the following steps: adding the longan pulp, wolfberry fruit, angelica and chrysanthemum flower into a cloth bag, putting into a container, adding the white wine, sealing, immersing for 30 days, and filtering to remove slag. The wine has the effects of nourishing the blood, moisturizing the skin and tonifying the liver and the kidney. The wine is mainly used for treating weak body, rough skin, aging and other symptoms. The wine is orally taken 10-15ml a time, twice a day.
PROBLEM TO BE SOLVED: To obtain a skin roughness-preventing agent comprising two kinds of such specific polymers as giving a blend film having a specific light transmittance, especially effective for preventing and improving skin roughness accompanied by inflammation, not irritating skin, and high in safety. SOLUTION: This agent for preventing the roughness of skin comprises (A) a polymer high in skin adhesivity and (B) a polymer having a moisture permeation coefficient of <=1×10<-5> cm<3> (STP) cm/cm<2> .sec.cmHg. A 100μm thick film comprising the blend of the polymers (A) and (B) has a light transmittance of >=50% at 530nm. The components (A) and (B) are compounded in a weight ratio of 10/90 to 90/10. The component (A) includes acidic heterogeneous polysaccharides, and the polymer (B) includes polyvinyl alcohol. The skin roughness-preventing agent is high in adhesivity to the skin, and can shut irritation from the outsides, reduce the evaporation of water from skin surface and inhibit the advance of cornification.
Procedure of the synthesis of derivatives of ciloheptal (1,283-hi) tieno (3,4-c) piridina and ciclohepa (1,2,3-de) isoquinolina, of formula (I) being xey sulfur or a group of formula (II). A formula (III) cetone with triethyphisphon acetate and sodium hydride, in dry tetrahydrofuran or reflux, is reactioned. The product is hydrolyzed in a sodium or potassium hydroxide mixture, and the iliden-acetic acid obtained is treated with a sodium azide, in tetrahydrofuran as solvent. The organic phase is separated, dryed on magnesic sulphate and concentrated at reduced pressure. It is warmed in a solid apertar solvent and the product is collected at the end by filtration. (Machine-translation by Google Translate, not legally binding)
In the Treatment Phase, E6011 200 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
Objective: Analyze the effects of different physical therapies (Aquatic Jogging, Neurofunctional Physiotherapy, Pilates Training and Nordic Walking) and Dance and compare with unsupervised home exercises in the clinical-functional parameters, postural balance, muscular echographic quality, pendulum gait mechanism, and serum levels of brain-derived neurotrophic factor (BDNF) in people with Parkinson's disease with camptocormia or Pisa Syndrome. Experimental Design: Randomized controlled clinical trial with translational study characteristics. Search Location: Exercise Research Laboratory at the School of Physical Education, Physiotherapy and Dance, Federal University of Rio Grande do Sul, and in the Movement Disorders Outpatient Clinic of the Hospital of Clinicals of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil. Participants: 100 patients from the Unified Health System (UHS) of both sexes, from 50 to 80 years old, diagnosed with idiopathic PD, sedentary. Interventions: In this research, four groups of patients with PD will receive intervention during 4 months of different physical therapy programs (Nordic walking, aquatic jogging and supervised neurofunctional physiotherapy) and dance; and a control group, who will receive telephone guidance for performing home-based exercises. The training programs will have a duration of 4 months and will be periodized so that the duration of the sessions is matched between them. The intensity of the interval training will be manipulated by the subjective effort scale (Borg) and by the heart rate, with predetermined series durations. All training programs will have a frequency of two sessions per week and a duration of 60 minutes. In order to evaluate the effects of the training, evaluations will be performed before and after the training period: 1) Basal (month 0): initial pre-training evaluation; 2) month 4: Evaluation 48h after the last training session. Outcomes: clinical-functional parameters, postural balance, muscular echographic quality, pendulum gait mechanism, and biochemistry. Data Analysis: Data will be described by average values and standard deviation values. The comparisons between and within groups will be performed using a Generalized Estimating Equations (GEE) analysis, adopting a level of significance (α) of 0.05. Expected Results: The intervention groups of the different physical therapies and dance are expected to be more effective in all outcomes analyzed, especially improving functional mobility when compared to the control group of unsupervised home exercises. In addition, it is expected that the results of the research will be expandable and the possibility of future developments in the scientific, technological, economic, social and environmental fields and that they will be implemented in the Unified Health System (UHS).
For Group B, Bolster dressing was done to secure split thickness skin graft. The recipient site was bolstered with wet bulky cotton gauze dressing and wrapped with cotton bandage. 0.9% normal saline was used for moisture.
BACKGROUND: A significant proportion of patients with clinical stage IA non-small cell lung cancer (NSCLC) experience will recurrence and decreased survival after surgery. This study examined the impact of preoperative primary tumor positron emission tomography (PET) scan maximum standardized uptake value (SUVmax) on oncologic outcomes after surgery.
METHODS: This was a retrospective review of 251 patients who underwent surgical treatment of clinical stage IA NSCLC at an academic medical center (2005-2014). Patients were classified according to PET SUVmax level (low vs high) for analysis of upstaging, tumor recurrence, and overall survival.
RESULTS: Median SUVmax values were higher in squamous cell carcinoma than in adenocarcinoma (median 3.3 vs 7.2; P < .0001). There were 109 (43.4%) patients in the SUVmax low group and 142 (56.6%) in the SUVmax high group. Patients with SUVmax high had larger tumors. SUVmax high was associated with higher rates of nodal upstaging (16.2% vs 4.6% in SUVmax low; P = .004), particularly in N1 nodes. SUVmax high was independently associated with nodal upstaging (adjusted odds ratio, 3.95; 95% CI, 1.36-11.46; P = .011). SUVmax high was associated with time to recurrence (hazard ratio, 1.62; 95% CI, 1.03-2.54; P = .036), but this association was lost on multivariable analysis (hazard ratio, 1.52; 95% CI, 0.91-2.54; P = .106). SUVmax was not associated with overall survival.
CONCLUSIONS: Preoperative PET SUVmax level is strongly associated with nodal upstaging, particularly in N1 nodes, in patients with clinical stage IA NSCLC who undergo resection. PET SUVmax should be regarded as a risk factor when considering candidacy for sublobar resections and in future trials involving patients with stage I NSCLC.
A haemoglobin prepn. of intravenous injection, having a high oxygen liberating power compared to erythrocytes and haemoglobin solns. comprises a haemoglobin-pyridoxal phosphate condensn. prod. causing no pyrogenic reactions and having a life of 2-9 hours in the circulatory system. In an example erythrocytes were mixed with NaCl and beta-propiolactone soln, then washed with aq. NaHCO3 and NaCl Haemolysis was effected using Dowex 50WX 8(RTM) H+ form, adjusted to pH 5.5-5.7 and sepd. The supernatant soln. was diluted, adjusted to pH 7.5 washed and oxygen eliminated, with N2. It was then treated with pyridoxal-5-phosphate monohydrate (3.5. moles per mole of haemoglobin tetramer) stirred for 1 hr. at 20 degrees C and washed. The prod. was filtered off at pH 7.6.
Before induction of general anesthesia thoracic paravertebral block was performed. General anaesthesia was induced with midazolam 0.1 mg\*kg-1, propofol 2 mg\*kg-1, cisatracurium 0.15 mg\*kg-1 and fentanyl 1.5 µg\*kg-1. Anaesthesia was maintained with one minimal alveolar concentration sevoflurane. Fractional doses of fentanyl 1-3 µg\*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced. After surgery, if a patient complained of pain then she/he was given i.v. oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA). The PCA solution was oxycodone (1mg\*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min. During the night, basal rate oxycodone was 2-4 mg per hour. Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.